摘要
目的研究前B细胞克隆增强因子(PBEF)在中性粒细胞缺乏状态合并脓毒症时的水平变化及临床应用价值。方法选取28例急性淋巴细胞白血病(ALL)化疗后处于中性粒细胞缺乏状态的患儿为研究对象,其中无感染14例,脓毒症14例。收集所有患儿的临床资料及血清标本,用酶联免疫吸附法(ELISA)检测PBEF浓度,比较两组PBEF水平,分析PBEF与临床常用感染指标CRP、PCT的相关性,探讨中性粒细胞缺乏时PBEF在脓毒症的临床应用价值。结果脓毒症组PBEF浓度为(5.526±1.548)ng/mL,无感染组PBEF浓度为(5.184±1.295)ng/mL,两组PBEF水平比较无明显差异(p=0.536)。脓毒症组PBEF与其他常见炎性指标CRP、PCT无显著相关(尸值分别为0.159和0.311)。结论中性粒细胞缺乏状态合并脓毒症时PBEF水平无明显改变,可能与外周血中合成和分泌PBEF的细胞减少相关,PBEF是否可作为感染指标应用于临床有待进一步探讨。
Objective To investigate the level and clinical significance of serum pre-B-cell colony-enhancing factor (PBEF) in sepsis children with neutropenia. Methods We selected 28 cases of chemotherapy-induced neutropenia in childhood acute lymphoblastic leukemia, including 14 cases without infectious complications and 14 cases with sepsis. Serum specimens and clinical data from all enrolled children were collected. Serum level of PBEF was detected by enzyme-linked immunosorbent assay (ELISA). Compared serum PBEF level of two groups and analyzed the correlations between PBEF and other clinical infectious biomakers, such as CRP and PCT, and discussed the clinical application value of PBEF in sepsis with neutropenia. Results Serum PBEF level in sepsis group was (5. 526 ± 1. 548) ng/mL, in patients without infectious complications it was ( 5. 184 ± 1. 295 ) ng/mL. There was no significant difference in serum PBEF level between two groups (P = 0. 536 ). PBEF has no correlations with clinical infectious biomakers CRP or PCT. Conclusions Serum level of PBEF has no significant change in children with neutropenia, it may result from the lack of blood cells to synthesize and secrete PBEF, further researches are needed to establish whether PBEF can used as a maker for infection.
出处
《中国小儿血液与肿瘤杂志》
CAS
2016年第2期98-101,103,共5页
Journal of China Pediatric Blood and Cancer
基金
国家自然科学基金(No.81060045)
国家自然科学基金(No.81170482)
广西壮族自治区研究生创新课题项目(YCSZ2014100)